Showing 181 - 200 of 244 results
The new trilateral security partnership between Australia, the UK and the US (AUKUS) is a historically significant development for nuclear science and technology in Australia.
Health Products pricing, effective from 1 October 2024.
Health Products pricing, effective from 1 October 2024.
$80.2 million in new funding to expand the research capabilities of the Australian Synchrotron.
Australia and Sri Lanka develop action plan to fight Chronic Kidney Disease killer
Charcoal particles from recent bushfires in NSW were carried 50 kilometres by the wind, which has significance for fire history reconstruction.
The ANSTO Awards in Nuclear Science and Technology 2018 were presented on Friday 2 November at The Australian Museum, and showcased ANSTO’s unique nuclear science and technology capabilities, which enable progress in the key areas of health research and innovation for industry.
Research and development activity explores new, boutique radioisotopes, including positron, gamma and beta/gamma emitter. The aim is to provide material for the next generation of diagnostic and therapeutic radiopharmaceuticals
Modified component of green tea promises potential neuroblastoma treatment.
Wombat used in study that showed tuneable thermal expansion by controlled gas sorption.
ANSTO recently re-started the OPAL Reactor after a six-month shutdown for essential maintenance and the installation of an upgraded facility.
The User Advisory Committee (UAC) are pleased to present this year's invited speakers.
Earlier this month, ANSTO welcomed a delegation of Elders from the Willandra Lakes Region World Heritage site to its Lucas Heights campus. The visit marked a significant collaboration between Traditional Custodians and scientists working to uncover the environmental history of Lake Mungo.
Thales Australia, a key supplier to the Australian Defence Forces, provided an industrial challenge to National Graduate Innovation Forum participants relating to the production of piezoelectric ceramic components used in naval sonar arrays and systems.
The protein mapping workhorses of the Australian Synchrotron, Macromolecular and Microfocus crystallography beamlines, MX1 and 2, continue to support important biomedical research in the development of vaccines and new therapeutics.